Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756830 | 0.88 | MAPT (0.41) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL2181945 | 0.85 | POLB (0.40) | MAPTPOLBSMN1; SMN2LMNAUSP2 | |
| SCHEMBL12756832 | 0.84 | POLB (0.40) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL1490470 | 0.83 | ANO1 (0.41) | MAPTPOLBSMN1; SMN2HTT | |
| SCHEMBL15480665 | 0.82 | MAPT (0.41) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL12756829 | 0.81 | MAPT (0.44) | MAPTPOLBSMN1; SMN2LMNA | |
| SCHEMBL12756823 | 0.81 | ALDH1A1 (0.45) | MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL12756807 | 0.81 | MAPT (0.44) | MAPTPOLBSMN1; SMN2LMNAUSP2 | |
| SCHEMBL12830911 | 0.80 | SMN1; SMN2 (0.47) | MAPTPOLBSMN1; SMN2LMNAUSP2 | |
| SCHEMBL14692953 | 0.73 | SMN1; SMN2 (0.42) | MAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MAPT 1478/4885POLB 4774/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.